52 Grants (Page 1 of 3)
2021
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-09), $493,726USD, 2013-01-01 -- 2023-02-28
 
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA231267-04), $460,814USD, 2018-09-10 -- 2023-08-31
 
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA205166-05), $537,592USD, 2017-04-01 -- 2022-03-31
2020
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-08), $493,726USD, 2013-01-01 -- 2023-02-28
 
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA231267-03), $460,814USD, 2018-09-10 -- 2023-08-31
 
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA205166-04), $537,592USD, 2017-04-01 -- 2022-03-31
2019
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-07), $563,735USD, 01/01/2013 -- 02/28/2023
 
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA231267-02), $446,989USD, 09/10/2018 -- 08/31/2023
 
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA205166-03), $521,463USD, 04/01/2017 -- 03/31/2022
2018
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA167291-06S1), $227,554USD, 03/09/2018 -- 02/28/2020
 
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2R01CA167291-06), $493,726USD, 01/01/2013 -- 02/28/2023
 
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
Fehrenbacher, Jill C and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA231267-01), $460,814USD, 09/10/2018 -- 08/31/2023
 
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA205166-02), $483,834USD, 04/01/2017 -- 03/31/2022
2017
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-05), $444,566USD, 01/01/2013 -- 12/31/2017
 
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA205166-01A1), $536,312USD, 04/01/2017 -- 03/31/2022
2016
DNA damage and repair in inflammation-induced peripheral sensitization
Fehrenbacher, Jill C⋅Kelley, Mark R and VASKO, MICHAEL R
National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) (ID: 5R21NS091667-02), $195,000USD, 02/01/2015 -- 01/31/2018
 
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 4R01CA167291-04), $493,963USD, 01/01/2013 -- 12/31/2017
2015
DNA damage and repair in inflammation-induced peripheral sensitization
Kelley, Mark R and VASKO, MICHAEL R
National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) (ID: 1R21NS091667-01), $234,000USD, 02/01/2015 -- 01/31/2017
 
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-03), $493,963USD, 01/01/2013 -- 12/31/2015
2014
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA167291-02), $479,144USD, 01/01/2013 -- 12/31/2017
2013
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression
Fishel, Melissa L and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA167291-01A1), $493,963USD, 01/01/2013 -- 12/31/2017
 
Novel Therapeutic Strategy for Refractory and Relapse Childhood Acute Leukemia
HASLANGER, MARTIN F and Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R43CA171344-01A1), $240,322USD, 07/01/2013 -- 06/30/2015
2012
The Role of Ape1 in Neurotoxicity of Cancer Treatments
Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA121168-05), $405,107USD, 04/01/2008 -- 01/31/2014
2011
The Role of Ape1 in Neurotoxicity of Cancer Treatments
Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA121168-04), $403,464USD, 04/01/2008 -- 01/31/2013
2010
The Role of Ape1 in Neurotoxicity of Cancer Treatments
Kelley, Mark R
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA121168-03), $414,074USD, 04/01/2008 -- 01/31/2013